Research programme: cannabis extract therapeutics - Cannabis Science

Drug Profile

Research programme: cannabis extract therapeutics - Cannabis Science

Alternative Names: CS-S/BCC-1; CS-TATI-1; Phytocannabinoid-based pharmaceutical products - Cannabis Science

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cannabis Science
  • Developer Cannabis Science; Italian Institute for Health and Science on Ageing
  • Class Antineoplastics; Cannabinoids; Skin disorder therapies
  • Mechanism of Action Cannabinoid receptor modulators; Human immunodeficiency virus tat gene product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Adult respiratory distress syndrome; Cancer; HIV infections; Kaposi's sarcoma; Pain; Post-traumatic stress disorders; Respiratory tract disorders; Skin cancer; Sleep disorders
  • Research Anxiety disorders; Attention-deficit hyperactivity disorder; Autistic disorder; Fibromyalgia; Neuropathic pain

Most Recent Events

  • 02 Nov 2016 Early research in Fibromyalgia in USA (Transdermal)
  • 02 Nov 2016 Early research in Neuropathic pain in USA (Transdermal)
  • 12 Aug 2016 Preclinical trials in Respiratory tract disorders in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top